Study #2021-0916
A phase II study of the combination of Azacitidine and Pembrolizumab for patients relapsed/refractory Hodgkin's lymphoma and acute myeloid leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Azacytidine, Pembrolizumab
Description
This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hodgkin's Lymphoma
Study phase:
Phase II
Physician name:
David McCall
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.